Skip to main content

Research Repository

Advanced Search

All Projects (75)

Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction Jan 11, 2017 - Jan 31, 2022
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven trial of MK-1242 (vericiguat) in subjects with heart failure with reduced ejection
fraction (HFrEF).
Approximately 4872 subjects will be randomized g... Read More about Victoria: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Centre Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerlCiguaT Gloobal Study in Subjects With Heart Failure With Reduced Ejection Fraction.

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Aug 31, 2022
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.... Read More about Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Aug 31, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - w... Read More about IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial.

PEOPLE: Primary care and community Engagement to Optimise time to Presentation with Lung cancEr symptoms in HULL Jun 1, 2017 - Jun 30, 2023
More people are diagnosed with and die from lung cancer in Hull than any other place in Yorkshire. Our aim is to improve earlier diagnosis of lung cancer by [1] getting people to see their doctor if they get lung symptoms and [2] getting GPs to refe... Read More about PEOPLE: Primary care and community Engagement to Optimise time to Presentation with Lung cancEr symptoms in HULL.

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study drug whic... Read More about Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.

A multi-centre, randomized, double-blind, placebo-controlled phase II study to assess the effect of Serelaxin versus placebo on high-sensitivity cardia troponin I (hs-cTnl) release in patients with chronic heart failure after exercise when used in additio Feb 18, 2016 - Feb 17, 2017
Numerous pathophysiological mechanisms are responsible for heart failure such as myocardial injury, oxidative stress, neuro-hormonal activation, inflammation, fibrosis and apoptosis. Besides B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT... Read More about A multi-centre, randomized, double-blind, placebo-controlled phase II study to assess the effect of Serelaxin versus placebo on high-sensitivity cardia troponin I (hs-cTnl) release in patients with chronic heart failure after exercise when used in additio.

PARAGON: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction Apr 1, 2015 - Mar 31, 2020
Cardiovascular (CV) disease is the leading cause of death in the western world. Heart failure (HF) incidence approaches 10 per 1000 population after 65 years of age in the United States (US) (Roger et al 2012) with HF prevalence between 2 and 3% in E... Read More about PARAGON: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.

SOLOIST: A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Effects of SOtagliLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POST worsening Heart Failure. Aug 1, 2018 - Jan 31, 2021
A Randomized, Double-Blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Effects of SOtagliLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POST worsening Heart Failure.